×
Jeśli w ciągu kilku sekund nie nastąpi przekierowanie, kliknij
tutaj
.
Wszystko
Grafika
Wideo
Wiadomości
Mapy
Zakupy
Książki
Narzędzia wyszukiwania
Szukaj w internecie
Szukaj w internecie
Tylko język polski
Najnowsze
Najnowsze
Ostatnia godzina
Ostatnie 24 godziny
Ostatni tydzień
Ostatni miesiąc
Ostatni rok
Archiwa
Według trafności
Według trafności
Według daty
IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer
OncLive
China's NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ...
4 dni temu
PRIME® Online Activity - Expert Perspectives on New and Emerging Biomarkers and Targeted Therapy Options for G ...
PRIME® Continuing Medical Education
Activity Overview · See how your knowledge compares with that of other clinicians in interactive questions and case-based scenarios · Download a convenient,...
3 miesiące temu
Cadonilimab Plus Chemo Provides Survival Benefit in Gastric/GEJ Cancer
Oncology Nursing News
Patients with gastric/GEJ adenocarcinoma treated with cadonilimab plus oxaliplatin and capecitabine obtained a survival benefit regardless...
miesiąc temu
Bispecific Checkpoint Inhibitor Improves Survival in Advanced Gastric/GEJ Cancer
MedPage Today
SAN DIEGO -- A bispecific immune checkpoint inhibitor significantly improved survival in advanced gastric/gastroesophageal junction (GEJ)...
miesiąc temu
Debate Assesses FLOT vs CROSS in GEJ Adenocarcinoma
Targeted Oncology
Yanghee Woo, MD, discusses a debate which focused on determining the best neoadjuvant therapy for patients with gastroesophageal junction...
miesiąc temu
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
Cancer Network
Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive...
6 miesięcy temu
Changes to Treatment for HER2-Positive Gastric Cancer
National Cancer Institute (.gov)
FDA recently announced separate approvals of pembrolizumab (Keytruda) for HER2-positive and HER2-negative gastric and gastroesophageal...
5 miesięcy temu
Perioperative Pembrolizumab Falls Short in Gastric, GEJ Cancer
Cancer Therapy Advisor
Adding pembrolizumab to perioperative chemotherapy did not improve survival outcomes in patients with resectable gastric or GEJ cancer.
4 miesiące temu
Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer
OncLive
Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.
miesiąc temu
PD-L1 CDx Earns FDA Approval to Identify PD-L1+ Gastric/GEJ Tumors
Cancer Network
Approval of PD-L1 IHC 22C3 pharmDx may also identify patients with non–small cell lung cancer and other malignancies who may benefit from...
5 miesięcy temu